Business
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
LONDON, October 15, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase I CLARITY open-label, crossover study, showing clinically relevant differences in injection site reaction (ISR) acceptability and tolerability, with 69% of HIV-negative adults finding cabotegravir long-acting (CAB LA) injections to be "totally or very acceptable" vs 48% for lenacapavir (LEN) injections. Data presented at
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":320,"height":296,"url":"https://media.zenfs.com/en/business-wire.com/c8e5c012467dbb0c98cf0bcc33dd3e22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IassT5Yjcsi4kVfQ630JAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTU5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c8e5c012467dbb0c98cf0bcc33dd3e22","width":320,"height":296}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Initial data from the CLARITY study are first to compare acceptability and tolerability of single-dose cabotegravir (CAB) and lenacapavir (LEN) long-acting injections, in 63 HIV-negative adults","length":193,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Sixty-nine percent of individuals found CAB injections to be ‘totally or very acceptable’ versus 48% for LEN injections, and 90% of participants and 86% of healthcare providers preferred CAB injections over LEN","length":210,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Findings could help inform expectations and decision-making when initiating long-acting HIV injectables","length":103,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":506,"olType":false},{"type":"text","content":"LONDON, October 15, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase I CLARITY open-label, crossover study, showing clinically relevant differences in injection site reaction (ISR) acceptability and tolerability, with 69% of HIV-negative adults finding cabotegravir long-acting (CAB LA) injections to be "totally or very acceptable" vs 48% for lenacapavir (LEN) injections. Data presented at the 20th European AIDS Conference (EACS) in Paris, France, also showed 90% of HIV-negative adults and 86% of healthcare providers (HCPs) preferred CAB LA injections over LEN injections after a single dose, and ISR events were more frequent and visible with LEN than with CAB LA.1","length":807,"tagName":"p"},{"type":"text","content":"Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: "We believe long-acting innovations will play a critical role in the global response to e...